CA Patent

CA2037630C — Nitrogen-containing heterocylic compounds, their production and use

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2001-07-03 · 25y expired

What this patent protects

Abstract of the Disclosure Nitrogen-containing heterocyclic compounds of the formula (I): wherein Y is N or CH; R', which may be optionally bound through a hetero atom, is a hydrocarbon residue which may be substituted; R2 and R3 which may be same or different, are each…

USPTO Abstract

Abstract of the Disclosure Nitrogen-containing heterocyclic compounds of the formula (I): wherein Y is N or CH; R', which may be optionally bound through a hetero atom, is a hydrocarbon residue which may be substituted; R2 and R3 which may be same or different, are each independently hydrogen, cyano, nitro, optionally substituted lower alkyl, or -COD wherein D is alkoxy, hydroxy, halogen, or optionally substituted amino; or R2 and R3 are taken together to form a benzene ring which may be substituted; the dotted line is a chemical bond; Z is bound to a hetero nitrogen atom and is a group having the formula: wherein R4 is hydrogen, halogen or vitro, and R5 is a residue capable of forming an anion or a residue convertible into an anion; A is a direct bond or a spacer having atomic length of two or less between the phenylene group and the phenyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonist activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases, strokes, etc.

Drugs covered by this patent

Patent Metadata

Patent number
CA2037630C
Jurisdiction
CA
Classification
Expires
2001-07-03
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.